Gilead Sciences, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 30092017] Prices from USD $175
Gilead Sciences, Inc. Strategy, SWOT and Corporate Finance Report
Summary
Gilead Sciences, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.
Key Highlights
Gilead Sciences, Inc. Gilead or 'the company' is a researchbased biopharmaceutical company engaged in developing and marketing therapies for HIV/AIDS, liver diseases, oncology, inflammation and serious cardiovascular and respiratory conditions. The company operates in the US, Europe and other countries. It is headquartered in Foster City, California.
Scope
Detailed information on Gilead Sciences, Inc. required for business and competitor intelligence needs
A study of the major internal and external factors affecting Gilead Sciences, Inc. in the form of a SWOT analysis
An indepth view of the business model of Gilead Sciences, Inc. including a breakdown and examination of key business segments
Intelligence on Gilead Sciences, Inc.'s mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about Gilead Sciences, Inc., such as business expansion, restructuring, and contract wins
Large number of easytograsp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Gilead Sciences, Inc. and the factors that influence its strategies.
Track strategic initiatives of the company and latest corporate news and actions.
Assess Gilead Sciences, Inc. as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Gilead Sciences, Inc.'s business structure, strategy and prospects.
Original Article: Gilead Sciences, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 30092017] Prices from USD $175
